Bridger Management LLC Sells 286,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Bridger Management LLC lowered its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 29.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 695,000 shares of the company's stock after selling 286,000 shares during the period. Teva Pharmaceutical Industries comprises about 8.2% of Bridger Management LLC's portfolio, making the stock its 4th largest position. Bridger Management LLC owned about 0.06% of Teva Pharmaceutical Industries worth $15,318,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Beverly Hills Private Wealth LLC bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $213,000. BNP Paribas lifted its stake in shares of Teva Pharmaceutical Industries by 59.8% in the 4th quarter. BNP Paribas now owns 12,655 shares of the company's stock valued at $279,000 after purchasing an additional 4,737 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Teva Pharmaceutical Industries by 14.4% during the fourth quarter. BNP Paribas Financial Markets now owns 1,337,470 shares of the company's stock valued at $29,478,000 after buying an additional 168,699 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Teva Pharmaceutical Industries by 3.9% during the fourth quarter. Ameriprise Financial Inc. now owns 147,649 shares of the company's stock worth $3,254,000 after acquiring an additional 5,494 shares during the period. Finally, Alyeska Investment Group L.P. lifted its position in shares of Teva Pharmaceutical Industries by 0.5% in the 4th quarter. Alyeska Investment Group L.P. now owns 3,641,392 shares of the company's stock worth $80,256,000 after purchasing an additional 16,392 shares during the period. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded down $1.13 during mid-day trading on Friday, hitting $16.94. 19,072,081 shares of the company traded hands, compared to its average volume of 10,043,801. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The stock has a 50-day moving average price of $15.16 and a two-hundred day moving average price of $17.47. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The stock has a market cap of $19.21 billion, a price-to-earnings ratio of -11.68, a P/E/G ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm's revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.48 EPS. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on TEVA shares. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Finally, UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of "Buy" and an average target price of $23.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.